Details for New Drug Application (NDA): 050545
✉ Email this page to a colleague
NDA 050545 describes PIPRACIL, which is a drug marketed by Wyeth Pharms Inc and is included in two NDAs. Additional details are available on the PIPRACIL profile page.
The generic ingredient in PIPRACIL is piperacillin sodium. There are sixteen drug master file entries for this compound. Additional details are available on the piperacillin sodium profile page.
The generic ingredient in PIPRACIL is piperacillin sodium. There are sixteen drug master file entries for this compound. Additional details are available on the piperacillin sodium profile page.
Summary for 050545
| Tradename: | PIPRACIL |
| Applicant: | Wyeth Pharms Inc |
| Ingredient: | piperacillin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050545
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 3GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 4GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
